^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/08/2020
Excerpt:
…triple negative recurrent/stage IV breast cancer and germline BRCA1/2 mutations, the NCCN Panel has included platinum agents (cisplatin and carboplatin) as preferred treatment options.
Source:
Title:
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Excerpt:
...Patients with ER+ and/or PR+ may enroll ONLY if they are known carriers of a deleterious mutation in BRCA1 or BRCA2....
Trial ID:
Source:
Title:
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Published date:
06/10/2015
Excerpt:
Patients (N = 86; 69 as first-line therapy) received cisplatin (n = 43) or carboplatin (n = 43). RR was 25.6% (95% CI, 16.8% to 36%) and was numerically higher with cisplatin (32.6%) than with carboplatin (18.7%). RR was 54.5% in patients with germline BRCA1/2 mutations (n = 11)...Platinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations.
DOI:
10.1200/JCO.2014.57.6660
Trial ID:
Source:
Title:
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas
Published date:
07/06/2022
Excerpt:
To this end, we analyzed a cohort of 43 TNBC PDXs with known response to both single-agent platinum (either carboplatin, n = 36, or cisplatin, n = 7) and single-agent docetaxel….By contrast, 90.9% of BRCAmut PDXs (10 of 11; P = 0.005) had a response, including seven of eight BRCA1mut and three of three BRCA2mut models (Fig. 2C and table S3).
DOI:
10.1126/scitranslmed.abn1926
